Halucenex

Halucenex is a life sciences development company with a goal of exploring and producing new psychedelic compounds along with developing and licensing psychedelics for the pharmaceutical and nutraceutical markets, as well as conducting clinical trials on the medical efficacy of psychedelic medicine.

Halucenex operates a 6000 soft psychedelic-assisted psychotherapy and clinical research facility located in Windsor, Nova Scotia. It has six treatment rooms and a secure laboratory dedicated to conducting psychedelic-assisted psychotherapy and clinical study.

The company's goal is to maintain control over the product development process, including mycological research, extraction technology, and synthetic formulation as well as drug delivery techniques, psychedelic-assisted psychotherapy, and regulatory issues.

Psychedelic News

Wellbeing’s KGK Science Enters Phase II Clinical Trial Research Contract With Halucenex

Evidence-based mental healthcare company Wellbeing Digital Sciences Inc. (NEO: MEDI) (OTC: KONEF) (FRA: SQ2) announced that its wholly-owned subsidiary KGK Science Inc. has entered into

July 22, 2022

Halucenex

Wellbeing’s KGK Science Enters Phase II Clinical Trial Research Contract With Halucenex

Choose Ketamine Complete Capital Raise to Expand Technology Platform

Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Suggestions

Halucenex

Wellbeing’s KGK Science Enters Phase II Clinical Trial Research Contract With Halucenex

Choose Ketamine Complete Capital Raise to Expand Technology Platform

Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment